Strensiq
Chemical Name | asfotase alfa |
Dosage Form | Injection (subcutaneous; 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, 80 mg/0.8 mL) |
Drug Class | Miscellaneous |
System | Musculoskeletal |
Company | Alexion Pharmaceuticals Inc. |
Approval Year | 2015 |
Indication
- To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).